NEW YORK, NY / ACCESSWIRE / July 20, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=17811&wire=1
Lead Plaintiff Deadline: August 2, 2021
Class Period: November 16, 2020 - March 22, 2021
Allegations against FREQ include that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
RLX Technology Inc. (NYSE:RLX)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/rlx-technology-inc-loss-submission-form?prid=17811&wire=1
Lead Plaintiff Deadline: August 9, 2021
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the documents issued in connection with RLX's January 2021 initial public stock offering.
Allegations against RLX include that: the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.
Ocugen, Inc. (NASDAQ:OCGN)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ocugen-inc-loss-submission-form?prid=17811&wire=1
Lead Plaintiff Deadline: August 17, 2021
Class Period: February 2, 2021 - June 10, 2021
Allegations against OCGN include that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong